Literature DB >> 7721952

Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence.

E H Sage1, J A Bassuk, J C Yost, M J Folkman, T F Lane.   

Abstract

SPARC (secreted protein, acidic and rich in cysteine, also known as osteonectin and BM-40) is a metal-binding glycoprotein secreted by a variety of cultured cells and characteristic of tissues undergoing morphogenesis, remodeling, and repair. Recently it has been shown that SPARC inhibits the progression of the endothelial cell cycle in mid-G1, and that a synthetic peptide (amino acids 54-73 of secreted murine SPARC, peptide 2.1) from a cationic, disulfide-bonded region was in part responsible for the growth-suppressing activity [Funk and Sage (1991): Proc Natl Acad Sci USA 88:2648-2652]. Moreover, SPARC was shown to interact directly with bovine aortic endothelial (BAE) cells through a C-terminal EF-hand sequence comprising a high-affinity Ca(2+)-binding site of SPARC and represented by a synthetic peptide (amino acids 254-273) termed 4.2 [Yost and Sage (1993): J Biol Chem 268:25790-25796]. In this study we show that peptide 4.2 is a more potent inhibitor of DNA synthesis that acts cooperatively with peptide 2.1 to diminish the incorporation of [3H]-thymidine by both BAE and bovine capillary endothelial (BCE) cells. At concentrations of 0.019-0.26 mM peptide 4.2, thymidine incorporation by BAE cells was decreased incrementally, relative to control values, from approximately 100 to 10%. Although somewhat less responsive, BCE cells exhibited a dose-responsive decrement in thymidine incorporation, with a maximal inhibition of 55% at 0.39 mM. The inhibitory effect of peptide 4.2 was essentially independent of heparin and basic fibroblast growth factor and was blocked by anti-SPARC peptide 4.2 IgG, but not by antibodies specific for other domains of SPARC. To identify residues that were necessary for inhibition of DNA synthesis, we introduced single amino acid substitutions into synthetic peptide 4.2 and tested their activities and cell-surface binding characteristics on endothelial cells. Two peptides displayed null to diminished effects in the bioassays that were concentration-dependent: peptide 4.2 K, containing an Asp258 --> Lys substitution, and peptide 4.2 AA, in which the two disulfide-bonded Cys (positions 255 and 271) were changed to Ala residues. Peptide 4.2 K, which failed to fulfill the EF-hand consensus formula, exhibited an anomalous fluorescence emission spectrum, in comparison with the wild-type 4.2 sequence, that was indicative of a compromised affinity for Ca2(+).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721952     DOI: 10.1002/jcb.240570113

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  12 in total

1.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system.

Authors:  Barbara J Schiemann; Jason R Neil; William P Schiemann
Journal:  Mol Biol Cell       Date:  2003-06-27       Impact factor: 4.138

2.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Authors:  S Gately; P Twardowski; M S Stack; D L Cundiff; D Grella; F J Castellino; J Enghild; H C Kwaan; F Lee; R A Kramer; O Volpert; N Bouck; G A Soff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40.

Authors:  E Hohenester; P Maurer; R Timpl
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins.

Authors:  S A Rempel; W A Golembieski; J L Fisher; M Maile; A Nakeff
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

5.  Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo.

Authors:  M L Iruela-Arispe; T F Lane; D Redmond; M Reilly; R P Bolender; T J Kavanagh; E H Sage
Journal:  Mol Biol Cell       Date:  1995-03       Impact factor: 4.138

6.  Molecular tuning of an EF-hand-like calcium binding loop. Contributions of the coordinating side chain at loop position 3.

Authors:  S K Drake; M A Zimmer; C Kundrot; J J Falke
Journal:  J Gen Physiol       Date:  1997-08       Impact factor: 4.086

Review 7.  Identification and functional clustering of global gene expression differences between age-related cataract and clear human lenses and aged human lenses.

Authors:  J R Hawse; J F Hejtmancik; J Horwitz; M Kantorow
Journal:  Exp Eye Res       Date:  2004-12       Impact factor: 3.467

8.  Identification and functional clustering of global gene expression differences between human age-related cataract and clear lenses.

Authors:  John R Hawse; James F Hejtmancik; Quingling Huang; Nancy L Sheets; Douglas A Hosack; Richard A Lempicki; Joseph Horwitz; Marc Kantorow
Journal:  Mol Vis       Date:  2003-10-07       Impact factor: 2.367

9.  SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.

Authors:  Angela Chew; Paul Salama; Anneli Robbshaw; Borut Klopcic; Nikolajs Zeps; Cameron Platell; Ian C Lawrance
Journal:  PLoS One       Date:  2011-07-26       Impact factor: 3.240

10.  Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance.

Authors:  C-S Wang; K-H Lin; S-L Chen; Y-F Chan; S Hsueh
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.